Gene Variant Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Gene FLT3
Variant exon17
Impact List unknown
Protein Effect unknown
Gene Variant Descriptions FLT3 exon 17, which corresponds to the tyrosine kinase domain, indicates an unspecified mutation has occurred in exon 17 of the FLT3 gene.
Associated Drug Resistance
Category Variants Paths

FLT3 mutant FLT3 exon17

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

No Variant Reference Transcript is Available.
No transcript is Available.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT05554393 Phase II Cytarabine + Daunorubicin Cytarabine + Daunorubicin + Venetoclax Azacitidine + Venetoclax Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) Recruiting USA | CAN 1
NCT05766514 Phase II Cladribine + Cytarabine + Decitabine Decitabine + Venetoclax Azacitidine + Venetoclax Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction Not yet recruiting USA 0
NCT05330377 Phase I Cladribine + Cytarabine + Filgrastim + Gilteritinib + Mitoxantrone GM-CLAG in Relapsed/Refractory FLT3-mutated AML Withdrawn USA 0
NCT04817241 Phase Ib/II Cytarabine + Daunorubicin Decitabine and Cedazuridine + Venetoclax Testing Oral Decitabine and Cedazuridine (ASTX727) in Combination With Venetoclax for Higher-Risk Acute Myeloid Leukemia Patients Active, not recruiting USA 0
NCT04669067 Phase Ib/II KRT-232 + TL-895 TL-895 and KRT-232 Study in Acute Myeloid Leukemia Active, not recruiting USA | ITA | FRA | ESP | DEU | AUT | AUS 1
NCT05554406 Phase II Cytarabine + Daunorubicin Azacitidine + Venetoclax CPX-351 Cytarabine + Daunorubicin + Venetoclax CPX-351 + Venetoclax Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) Recruiting USA 1
NCT05756777 Phase I Gilteritinib + Ivosidenib Enasidenib + Gilteritinib A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML) Recruiting USA 0
NCT05886049 Phase I Cytarabine + Daunorubicin + Revumenib Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene Recruiting USA 0
NCT04168502 Phase III Gemtuzumab ozogamicin + Glasdegib Gemtuzumab ozogamicin Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML Recruiting ITA 0
NCT05024552 Phase I CPX-351 + Gilteritinib Vyxeos Plus Gilteritinib in Relapsed or Refractory, FLT3-Mutated AML Recruiting USA 0
NCT05558124 Phase I CPX-351 + Gemtuzumab ozogamicin CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML Recruiting USA 0
NCT06152809 Phase I Aldesleukin + CIML-NK cells + Venetoclax CIML NK Cells With Venetoclax for AML Active, not recruiting USA 0
NCT06366789 Phase I ZE46-0134 Dose Escalation and Expansion Study to Evaluate the Safety, PK, PD and Efficacy of ZE46-0134 in Adults With FLT3 Mutated Relapsed or Refractory Acute Myeloid Leukemia Not yet recruiting AUS 0
NCT04385290 Phase Ib/II Cytarabine + Daunorubicin + Gemtuzumab ozogamicin + Midostaurin Cytarabine + Daunorubicin + Gemtuzumab ozogamicin Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) (MOSAIC) Recruiting DEU 0
NCT06313437 Phase I Cytarabine + Daunorubicin + Midostaurin + Revumenib Cytarabine + Midostaurin + Revumenib Revumenib in Combination With 7+3 + Midostaurin in AML Not yet recruiting USA 0
NCT05697510 Phase I Siltuximab Dose-escalation of Siltuximab in Combination With Idarubicin and Cytarabine Chemotherapy in Patients With Acute Myeloblastic Leukaemia (AML) With Poor Prognosis: SILTUXILAM (SILTUXILAM) Recruiting FRA 0
NCT03922100 Phase Ib/II NMS-P088 Study of NMS-03592088 in Patients With Relapsed or Refractory AML or CMML Terminated ITA | FRA | ESP 0
NCT04027309 Phase III Midostaurin Gilteritinib A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML) Active, not recruiting SWE | NOR | NLD | LUX | LTU | IRL | FRA | FIN | ESP | DEU | CHE | BEL | AUT | AUS 0
NCT06222580 Phase I Gilteritinib + Revumenib SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation Recruiting USA 0